94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ERRATUM article
Front. Physiol. , 12 December 2022
Sec. Striated Muscle Physiology
Volume 13 - 2022 | https://doi.org/10.3389/fphys.2022.1111059
This article is an erratum on:
Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
An Erratum on
Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
by Kawana M, Spudich JA and Ruppel KM (2022). Front. Physiol. 13:975076. doi: 10.3389/fphys.2022.975076
Due to a production error, there was a mistake in Table 1 as published. The references listed in the table were accidentally inverted. The corrected Table 1 appears below.
Due to a production error, the Reference for “Vera et al., 2019” was incorrectly written as “Vera, C. D., Johnson, C. A., Walklate, J., Adhikari, A., Svicevic, M., Mijailovich, S.M., et al. (2019). Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties. Biophysics. doi:10.1101/622738”. It should be “Vera, C. D., Johnson, C. A., Walklate, J., Adhikari, A., Svicevic, M., Mijailovich, S.M., et al. (2019). Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties. Biophysics. doi:10.1074/jbc.RA119.010563”. The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: myosin, hypertrophic cardiomyopathy, super relaxed state, mavacamten, omecamtiv mercarbil
Citation: Frontiers Production Office (2022) Erratum: Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies. Front. Physiol. 13:1111059. doi: 10.3389/fphys.2022.1111059
Received: 29 November 2022; Accepted: 29 November 2022;
Published: 12 December 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.